Humira Gets Expanded Approval for Psoriatic Arthritis | BlackDoctor

    Humira Gets Expanded Approval for Psoriatic Arthritis

    The Abbott Laboratories drug Humira (adalimumab) has been given expanded
    approval by the U.S. Food and Drug Administration to slow structural joint
    damage in people with psoriatic arthritis. The condition affects people who have
    skin psoriasis.

    Humira was initially
    approved for overall treatment of psoriatic arthritis in October 2005. It’s also
    been sanctioned to treat moderate-to-severe rheumatoid arthritis, and an
    inflammatory disease of the spine called ankylosing
    spondylitis.

    1 2Next page »

    Follow

    Get every new post delivered to your Inbox.

    Join 2,618 other followers